Opinion: If the Crypto Market Structure Act is passed, it will serve as a bullish catalyst
Svmuu News: Alex Thorn, Head of Research at Galaxy, posted on X that the U.S. Senate Banking Committee is set to vote on the Crypto Market Structure Act on January 15. Currently, the Senate is divided 53 to 47. Since bills typically require 60 votes to pass, Republicans still need the support of 7 to 10 Democratic senators. Alex Thorn noted that the bill addresses the classification of DeFi under anti-money laundering regulations, the treatment of stablecoin reserve earnings, protections for non-custodial developers, and the SEC’s authority or restrictions regarding token offerings. If the bill passes, it will serve as a major bullish catalyst for the widespread adoption of cryptocurrencies; if it fails, while the overall impact on industry fundamentals will be limited, it could lead to negative market sentiment.
Source:Odaily · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
Billionaire investor Chase Coleman’s Tiger Global fund disclosed in its latest 13F filing that its top five growth stocks are all focused on AI infrastructure, including TSMC, NVIDIA, Amazon, Meta, and Google.
-
2
Analysis of CRYSTAL’s Value and Investment Potential: An Examination of Multiple Projects and Risk Assessment
-
3
Will the BEAM token go to zero? Could it rise to $1,000? An in-depth analysis of the Beam network and its market prospects
-
4
The analysis points out that Iran’s overlapping centers of power complicate efforts to end the war with the United States, and that the Revolutionary Guards possess significant operational autonomy.
-
5
What Is CVP? An In-Depth Analysis of the PowerPool Ecosystem and the Investment Value of Its Token, CVP
-
6
What Is JGN? Analysis of the JGN (Sword Saint Coin) Project’s Positioning, Features, and Value
-
7
Analysis: The State Street Healthcare ETF (XLV) has an expense ratio of 0.08% and a diversified portfolio, while the Invesco Biotechnology ETF (PBE) has an expense ratio of 0.58% and focuses on small-cap stocks; PBE is up 10.2% year-to-date, outperforming XLV.
-
8
Analysis Compares Healthcare ETFs: Invesco Nasdaq Biotech ETF (IBBQ) Saw 45.5% One-Year Return, Outperforming State Street Healthcare Select Sector SPDR ETF (XLV)
-
9
Analysis: Vanguard Small-Cap Growth ETF (VBK) up 21% YTD 2026, Outperforming Large-Cap Growth ETF (VONG) at 0.3% YTD
-
10
QUARTZ Coin Analysis: An Overview of the Sandclock (QUARTZ) and Unique Network’s Quartz (QTZ) Projects
Markets Today
Recommended Reading







